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Abstract: The proteasome is responsible for the breakdown of cellular proteins. Proteins 
targeted for degradation are allowed inside the proteasome particle, where they are cleaved 
into small peptides and released in the cytosol to be degraded into amino acids. In vertebrates, 
some of these peptides escape degradation in the cytosol, are loaded onto class I molecules 
of the major histocompatibility complex (MHC) and displayed at the cell surface for  
scrutiny by the immune system. The proteasome therefore plays a key role for the immune 
system: it provides a continued sampling of intracellular proteins, so that CD8-positive  
T-lymphocytes can kill cells expressing viral or tumoral proteins. Consequently, the repertoire 
of peptides displayed by MHC class I molecules at the cell surface depends on proteasome 
activity, which may vary according to the presence of proteasome subtypes and regulators. 
Besides standard proteasomes, cells may contain immunoproteasomes, intermediate proteasomes 
and thymoproteasomes. Cells may also contain regulators of proteasome activity, such as 
the 19S, PA28 and PA200 regulators. Here, we review the effects of these proteasome 
subtypes and regulators on the production of antigenic peptides. We also discuss an 
unexpected function of the proteasome discovered through the study of antigenic peptides: 
its ability to splice peptides. 
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1. Introduction to the Ubiquitin Proteasome System 
The ubiquitin-proteasome system (UPS) is the major ATP-dependent protein degradation system  
in cells. It is essential to maintain cellular protein homeostasis and ensure the elimination of misfolded 
proteins (reviewed in [1,2]). Proteasome-dependent proteolysis is also essential to regulate a number of 
other cellular processes, such as cell differentiation, cell-cycle progression or apoptosis. Proteins targeted 
for degradation by the proteasome are tagged with polyubiquitin chains that are attached to lysine 
residues within the protein sequence. These ubiquitin-tagged proteins are recognized by the regulatory 
particle 19S (PA700), which is associated with the 20S proteasome catalytic core to form the 26S 
proteasome. Upon degradation, these ubiquitin-tagged proteins are degraded into small peptides of  
about three to 22 amino acids [3], which can be further degraded by cytosolic peptidases to recycle  
the pool of amino acids [4]. The immune system takes advantage of this system to monitor cellular 
integrity. Thus, a fraction of the peptides released by proteasomal degradation is transferred into the 
lumen of the endoplasmic reticulum (ER) by a dedicated transporter, named TAP (transporter associated 
with antigen processing) [5]. Inside the ER, those peptides will be further trimmed by ER-resident 
proteases, and peptides of an appropriate size (8–10 amino acids) and sequence will then associate with 
class I molecules of the major histocompatibility complex (MHC). Peptide-MHC complexes are finally 
displayed at the cell surface for potential recognition by cytolytic T-lymphocytes (CTLs). CTLs are 
major sentinels poised to rapidly recognize and destroy cells expressing mutant, infectious or tumoral 
proteins. It is the display of peptides (named antigenic peptides) derived from such altered proteins that 
marks cells for CTL recognition. The sensitivity of CTL, which can recognize target cells expressing  
as little as 10 molecules of antigenic peptide [6], enables the detection of only subtle changes in the 
cellular protein content. The detailed characterization of the antigenic peptides recognized by anti-tumor 
CTL that were isolated from the blood or tumor of cancer patients has provided valuable insights into 
the processing of antigenic peptides [7,8]. Such peptides usually derive from mutated proteins [9,10], 
from differentiation proteins [11,12] and from tumor proteins encoded by cancer-germline genes,  
such as the MAGE genes [13]. 
2. Role of the Proteasome in Antigen Processing 
The involvement of the proteasome in the production of MHC class I peptides was originally stressed 
by the observation that the presentation of the model antigen, ovalbumin, was dependent on 
ubiquitination and, therefore, on the 26S proteasome [14,15]. In line with this, MHC class I presentation 
was accelerated when the N-terminus of protein antigens was genetically modified with a bulky or  
a charged residue to increase their rate of ubiquitination by the ubiquitin ligase E3  (N-end rule) [16–18]. 
Another piece of evidence for the involvement of the proteasome in antigen processing came from  
the observation that proteasome inhibitors blocked the presentation of a number of antigenic peptides 
while limiting the overall peptide supply to MHC class I [19–27]. Although inhibitors reduced the cell 
ability to express specific antigenic peptides from full-length proteins, two studies showed that production 
of the antigenic peptides from minigenes of the correct size was not affected, suggesting that  
the inhibitors indeed specifically act on the peptide release from the full-length protein [19,28]. 
However, the role of proteasome inhibitors is often hard to interpret, first because inhibitors generally 
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induce ER stress, which can affect the rate of synthesis of some proteins [29,30], and second, because 
they inhibit some catalytic activities of the proteasome, but not others. Their effect may therefore vary 
according to the main catalytic activity involved in the production of the peptide studied. In addition, 
the production of a number of peptides depends on a balance between productive cleavages, occurring 
mostly at the C-terminus, and destructive cleavages occurring within the sequence of the antigenic 
peptide [31,32]. The net effect of proteasome inhibitors on the production of such peptides therefore 
depends on the relative inhibition of the catalytic activities responsible for the productive versus 
destructive cleavages [33]. Studies on the presentation of constructs involving antigenic peptides 
extended at the C-terminus or the N-terminus indicated that the proteasome was usually required to 
produce the C-terminal cleavage, but was dispensable for the N-terminal cleavage [28,34]. Subsequent 
studies showed that N-terminally extended peptide precursors produced by the proteasome can be further 
trimmed by other peptidases, either in the cytosol by tripeptidyl peptidase II (TPPII) [35] or, more 
prominently, in the ER by the endoplasmic reticulum aminopeptidase ERAP1 [36,37]. Another strong 
argument for the role of the proteasome in the production of class I peptides lies in the observation  
that many antigenic peptides are differentially processed by the various proteasomes subtypes,  
as we will discuss below (Table 1) [31,32,38]. 
Although the proteasome is considered as the main source of antigenic peptides, it is now clear that 
it is not the only protease able to generate antigenic peptides [27,39]. Several alternative cytosolic 
proteases were shown to process specific antigenic peptides, including tripeptidyl peptidase II (TPPII) and 
the metallopeptidases thimet oligopeptidase, nardilysin and insulin degrading enzyme (IDE) [40–44]. 
However, the function of these proteases in general MHC class I presentation appears quite limited [45–47]. 
Additionally, antigenic peptides can also be produced by proteases present in the ER or in the secretory 
compartment. For example, signal peptidase and/or signal peptide peptidase are both involved in the 
production of TAP-independent peptides derived from signal sequences [48,49]. Moreover, in cells with 
a defect in peptide loading complex quality control, trans-Golgi proteases, such as protease pro-protein 
convertase 7, can rescue a significant proportion of the unstable MHC class I peptides, potentially by 
making peptides available from full-length proteins [50]. Coupling a murine cytomegalovirus (CMV) 
epitope to the C-terminus of the secretory hepatitis B protein, HBe, Gil-Torregrosa et al. showed that 
the trans-Golgi resident protease, furin, which is involved in HBe maturation along the secretory route, 
helped with releasing the CMV peptide for loading onto H-2Ld in TAP-deficient cells [51]. Finally, 
another alternative pathway involved in the presentation of MHC class I-restricted peptides is autophagy, 
a process that enables non-proteasomal degradation of proteins at steady-state and in conditions of stress, 
such as starvation or oxidative damage. In the MHC class I pathway, autophagy appears to contribute to 
the processing of a growing number of antigenic peptides presented by MHC class I and derived from 
endogenously expressed proteins [52–54]. In the autophagy-based MHC class I processing, cellular 
proteins are brought to the autophagosome/lysosomal compartment for degradation, and the peptides 
released are then loaded onto local MHC class I. This process is TAP-independent and gives rise to 
peptides that can be similar to those produced through the classical proteasome processing pathway [52–54]. 
Although the relative importance of autophagy in antigen processing still needs to be evaluated further, 
this process may be important to circumvent viral or tumoral evasion strategies affecting TAP transport. 
In this review, we will recapitulate the role played by the proteasome and its regulators in the processing 
of antigenic peptides.
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Self        
RU134–42 HLA-B51 VPYGSFKHV + + §  +/ n.d. n.d. [20,31] 
FGF-5172–176 and 217–220 * HLA-A3 NTYAS_PRFK + +   n.d. n.d. [55,56] 
Differentiation        
gp10040–42 and 47–52 * HLA-A32 RTK_QLYPEW + +  +/ n.d. n.d. [22,56] 
gp100209–217 HLA-A2 ITDQVPFSV + +  +/ +/ +/ [12,31,38] 
gp100195–202 and 191 or 192 * HLA-A3 RSYVPLAH_R + + n.d. n.d. n.d. [57] 
Tyrosinase369377 HLA-A2 YMDGTMSQV + +  +/  +/ [31,38,58] 
Tyrosinase368–373 and 336–340 * HLA-A24 IYMDGT_ADFSF + +   n.d. n.d. [59] 
Melan-A26–35 HLA-A2 EAAGIGILTV + +  +/ +/ [38,60] 
Cancer germline        
MAGE-A3114–122 HLA-B40 AELVHFLLL  + + + + + + [31,38,61] 
MAGE-A3271–279 HLA-A2 FLWGPRALV   + +  [32,62] 
MAGE-A10254–262 HLA-A2 GLYDGMEHL    + + [32,63] 
MAGE-C2336–344 HLA-A2 ALKDVEERV  + +  + + [31,38,64] 
MAGE-C242–50 HLA-B57 ASSTLYLVF  + + + + + + [38,65] 
MAGE-C2191–200 HLA-A2 LLFGLALIEV    + + [38,64] 
Mutation        
CLPP240–248 HLA-A2 ILDKVLVHL +/ + +  n.d. n.d. [66] 
HAUS3154–162 HLA-A2 ILNAMIAKI  n.d. n.d. + + [67] 
Polymorphism (mHC ||)        
SP110296–301 and 286289 * HLA-A3 SLPRGT_STPK +/ + + n.d. n.d. [56,68] 
* Spliced peptide. § + +, efficiently produced; +/, slightly produced; , not produced; n.d., not determined. || mHC, minor histocompatibility antigen. 
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3. The 20S Proteasome 
The 20S proteasome is a cylindric particle of about 700 kDa, which is composed of four stacked 
heptameric rings, each comprising seven subunits. The two outer rings are identical and made of 
structural  subunits, and the two inner rings each contain seven  subunits, three of which mediate the 
catalytic activity of the proteasome: 1, 2 and 5 (Figure 1A). Mutagenesis studies and the analysis of 
the crystal structure of proteasomes complexed with inhibitors showed that peptide bond hydrolysis is 
mediated by the N-terminal threonine of the catalytically-active  subunits, which is exposed to  
the luminal side of the proteasome particle, in the catalytic chamber [69–72]. The hydroxyl group of  
the side chain of this threonine produces a nucleophilic attack on the carbonyl of the peptide bond, 
leading to the formation of an acyl-enzyme intermediate in which a peptide fragment remains attached 
to the proteasome by an ester link. Water molecules present in the chamber rapidly hydrolyze this  
acyl-enzyme intermediate, releasing a peptide fragment that is then transferred back into the cytosol [73]. 
A few years ago, we found that the proteasome was also able to produce antigenic peptides by creating 
a peptide bond between peptide fragments originally distant in the parental protein [22]. So far,  
five antigenic peptides were shown to be produced by this new function of the proteasome, called peptide 
splicing (Table 1) [22,55,57,59,68,74]. We showed that peptide splicing takes place in the proteasome 
chamber, through a process of transpeptidation that involves the nucleophilic attack of the acyl-enzyme 
intermediate by the N-terminus of a peptide fragment present in the catalytic chamber (Figure 2) [22]. 
Interestingly, among the five spliced peptides identified to date, three were composed of two  
non-contiguous peptide fragments spliced together in the reverse order to that in which they occur in  
the parental protein [57,59,68]. Given their nature, spliced antigenic peptides therefore appear as 
byproducts of the normal proteasome degradation activity. This process leads to the production of a large 
variety of peptides, as peptide splicing could theoretically involve any peptide fragment released by 
proteolysis, provided that the nucleophile peptide contains at least three amino acids [57]. Studying the 
peptide RSYVPLAH_R (splicing of fragment RSYVPLAH with a single arginine) derived from  
gp100 and presented by HLA-A3, we showed that this minimal size requirement for the nucleophile 
peptide resulted in the production of a spliced peptide bearing an extended C-terminus, which is then 
further trimmed by the proteasome in order to produce the final antigenic peptide (Figure 2) [57]. 
Recently, Mishto et al. suggested the existence of an additional pocket that would accommodate the 
nucleophile peptide and would be distinct from the primed substrate binding site, which accommodates 
the part of the peptide substrate located C-terminally from the cleavage site [75]. They suggested  
that this additional pocket might already be occupied by the splice reactant prior to the formation of  
the acyl-enzyme intermediate, thereby facilitating and speeding up the splicing reaction. This suggestion 
arose from their observation that the hierarchy of splicing at various sites within a given peptide did not 
strictly follow the hierarchy of cleavage at those sites, suggesting additional constraints determining 
splicing efficiency, such as the affinity of the nucleophile peptide for this postulated pocket. 
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Figure 1. Proteasome subtypes and regulators. (A) Mammalian proteasomes are composed 
of a 20S core particle, made of four stacked rings of seven subunits each. The two outer rings 
are made of  subunits, and the two inner rings are made of  subunits, three of which  
(1, 2, 5) are catalytically active. Upon induction with IFN or in immune cells, these 
catalytic subunits are replaced with their inducible counterparts, 1i, 2i, 5i, to form 
immunoproteasomes. Besides standard and immunoproteasomes, two additional forms of 
proteasome exist, which contain a mixture of standard and immune catalytic subunits,  
as indicated. The thymic cortex expresses a specific catalytic subunit, called 5t, which 
combines with 1i and 2i to form the thymoproteasome. The percentage of each proteasome 
type as measured by a sandwich ELISA approach [32] is indicated for different tissue and 
tumor types. Thymoproteasome is specifically expressed in cortical epithelial cells (cortical 
thymic epithelial cells (cTEC)). (B) The two -rings of the 20S proteasome interact  
with regulatory particles of four different types: PA700 (19S), PA28, PA28 and PA200. 
These regulatory particles can bind to one or both sides of the 20S particle or form  
hybrid proteasomes where the 20S core binds two different regulators. Representative examples 
are shown. NT, not tested. 
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Figure 2. Peptide splicing and trimming of the antigenic peptide RSYVPLAH_R derived 
from gp100 by the proteasome. In the course of peptide-bond hydrolysis, the hydroxyl group 
of the N-terminal threonine produces a nucleophile attack on the carbonyl of the peptide 
bond. This leads to the formation of an acyl-enzyme intermediate in which the peptide 
fragment RSYVPLAH remains attached to the proteasome through an ester link. Normally, 
this acyl-enzyme intermediate is rapidly hydrolyzed. However, peptide fragments, such as RGS, 
present in the chamber can compete with water molecules, their free N-terminal amino-group 
performing a nucleophilic attack on the acyl-enzyme intermediate. This transpeptidation 
leads to the creation of a new peptide bond, which assembles both fragments, leading to the 
formation of a spliced peptide bearing an extended C-terminus. The C-terminal extension is 
then further trimmed by the proteasome to release the antigenic peptide, RSYVPLAHR. 
Balls represent the catalytic  subunits of the proteasome. The hydroxyl group of the  
N-terminal threonine is indicated. 
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So far, the identification of spliced antigenic peptides has been limited by the availability of specific 
CTL directed against these peptides. Using a specific computer-based algorithm applied to the mass 
spectrometry analysis of peptide digests, Liepe at al. developed a novel approach (SpliceMet) to predict 
spliced antigenic peptides [76]. One could verify the relevance of these peptides by isolating CTL in vitro 
using the reverse immunology approach [77]. The presence of the predicted peptide at the surface of 
target cells would then be confirmed by analyzing the ability of these cells to activate the corresponding CTL. 
In essence, the proteolytic activity of the proteasome is not specific: any protein or peptide entering 
the proteasome can be degraded. It is therefore essential for cellular homeostasis to tightly control the 
activity of such an abundant intracellular protease, so as to prevent undesired degradation of intracellular 
proteins. The proteasome therefore evolved as a compartmentalized particle delineating a chamber that 
is not accessible to surrounding proteins and that contains the catalytically active sites [78]. This enables 
the control of proteasome activity at the level of the entry of substrates in the catalytic chamber. Indeed, 
regulators of proteasome activity, such as the 19S regulator, function as gate-keepers, allowing entry 
into the proteasome particle of only those substrates that need to be degraded and preventing entry of 
others. Entrance to the chamber is first limited by an aperture consisting of a 13-Å pore delimited by  
the ring formed by the  subunits, as observed in the Thermoplasma proteasome [69]. The small size of 
this -annulus ensures that only unfolded proteins can enter the catalytic chamber. Additionally,  
the entrance of the chamber is further obstructed in yeast and bovine proteasome by the N-terminal tails 
of the  subunits that form a tight polypeptide net, which is projected inside the pore and prevents access 
of smaller substrates to the catalytic chamber [70,79]. Free 20S proteasome therefore has a low activity, 
at least toward folded protein substrates [2]. Opening of the -gate is tightly regulated through  
the binding of specific activator complexes, called regulatory particles, which are believed to interact 
with the N-terminal tails of the -subunits, inducing their displacement and the opening of the gate [2]. 
Four types of regulators exist: the 19S regulator (PA700), the 11S regulators, PA28 and PA28,  
and the PA200 regulator, whose functions will be discussed below. 
As an exception to this rule of access-control by regulators, it has been shown that unfolded  
protein substrates and oxidant-damaged proteins can be degraded by free 20S proteasomes [80,81].  
A large excess of enzymatically-active, free 20S proteasome over 26S proteasome is indeed found within 
cells [82,83]. A recent study from Baugh et al. suggested that about 20% of total cellular proteins can 
be degraded by the 20S proteasome [84]. However, how unstructured proteins or oxidant-damaged 
proteins enter the catalytic core of the 20S chamber is still not well understood. Various studies suggested 
that access to the catalytic chamber could be controlled by the substrate itself or facilitated by accessory 
proteins, such as Hsp90 [85] or arginine-rich histones [86]. It has been suggested that hydrophobic 
patches that are often exposed after protein oxidation might facilitate the entry of oxidized proteins into 
the catalytic chamber [80], in line with the fact that hydrophobic peptides appear to promote the opening 
of the -ring of the 20S proteasome [87]. Conditions of stress, such as oxidative damage or prolonged 
starvation, induce 26S proteasomes to dissociate into 20S proteasomes and 19S sub-complexes [88–90]. 
This leads to a rapid decrease in proteolysis and an accumulation of ubiquitinated proteins, but could 
favor the degradation of poorly-structured or oxidized proteins by 20S proteasomes [88,91]. Reports 
have suggested that PA28 could also assist the 20S proteasome in the degradation of oxidized  
proteins [81,92]. 
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4. Regulation of the Proteasome Activity 
The first level of regulation is achieved by changes in the structure of the 20S proteasome, which 
exists in several isoforms or subtypes, having different catalytic activities. 
4.1. Proteasome Subtypes 
4.1.1. Standard Proteasome and Immunoproteasome 
In immune cells or after exposure to the inflammatory cytokines, IFN- or TNF-, alternative 
catalytic subunits, named LMP2 (1i), MECL-1 (2i) and LMP7 (5i), are expressed and incorporated 
into the proteasome in place of their constitutive counterparts, 1, 2 and 5, to form another particle 
called the immunoproteasome (Figure 1A) [93]. Based on the degradation of small fluorogenic peptides,  
three major catalytic activities of the proteasome were described, the caspase-like, trypsin-like and 
chymotrypsin-like activities, which cleave after acidic, basic and hydrophobic residues, respectively. 
The study of yeast proteasome mutants suggested that each of these catalytic activities was associated 
with one specific catalytic subunit. The caspase-like activity is linked to 1, while the trypsin-like and 
chymotrypsin-like activities are associated with 2 and 5, respectively [72,94,95]. However, it is now 
clear that the catalytic specificity is more complex than originally expected, since some proteasome 
subunits have overlapping specificities [95], and the position of the cleavage site can also be influenced 
by the surrounding residues [96,97]. Nevertheless, the immunoproteasome activity, as measured with 
fluorogenic peptides, is characterized by a lower caspase-like activity and higher trypsin-like and 
chymotrypsin-like activities [98,99]. Due to these differences in their catalytic sites, the standard proteasome 
and the immunoproteasome produce distinct peptide sets, which only partly overlap [97,98,100,101]. 
Because the immunoproteasome shows an increased propensity to cleave after basic or hydrophobic 
residues, it was predicted to be more efficient at producing antigenic peptides with high affinity for  
MHC class I molecules, which often call for peptides bearing basic or hydrophobic residues at  
their C-termini [98,100]. This idea was corroborated by the study of knockout mice for either 1i or 5i, 
in which the presentation of several epitopes was decreased [102,103]. This was recently confirmed  
using knockout mice for all three immunosubunits, whose dendritic cells fail to present a number of 
MHC class I epitopes and whose splenocytes display a peptide repertoire that is about 50% different 
from that of wild-type cells [104]. In the same line, the peptide repertoire of dendritic cells from 
2i/5i/ mice is less abundant and diverse than that of wild-type mice [105]. Overall, these results 
show that the immunoproteasome plays an important role in MHC class I antigen presentation. Several 
human tumor antigens are also better produced by the immunoproteasome than by the standard 
proteasome (Table 1) [31,32,38,61,65]. However, it is also clear that a number of antigenic peptides are 
better produced by the standard proteasome. The first example of such a peptide was described by  
Morel et al. who studied a human CTL clone recognizing a peptide derived from ubiquitous protein 
RU1. This peptide was presented by kidney cancer cells, but not by the autologous EBV-B cells [20]. 
This was explained by the fact that the peptide was processed efficiently by the standard proteasome, 
which was present in kidney cancer cells, but not by the immunoproteasome, which was abundant in  
the EBV-transformed B-cells. Other peptides that are efficiently processed by the standard proteasome,  
but not by the immunoproteasome, were subsequently identified (Table 1) [31,106]. In vitro digestions  
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of peptide precursors with purified proteasomes indicated that the lack of processing by one  
proteasome type generally resulted from a prominent cleavage within the antigenic peptide, resulting  
in its destruction [31,32,38]. Similar observations were made when Basler et al. studied the 
immunoproteasome-dependent generation of the murine minor histocompatibility antigen UTY246–254 
and the human influenza matrix peptide58–66 [107]. The authors showed that inhibition of the 1 or the 
5 subunit, respectively, rescued the presentation of these peptides, suggesting that the standard subunits 
were responsible for their degradation. 
In the past few years, we and others identified several peptides produced by peptide splicing in the 
proteasome. As described above, the peptide splicing reaction takes place in the proteasome trough  
a reaction of transpeptidation involving the nucleophilic attack of an acyl-enzyme intermediate by 
another peptide fragment present in the chamber [22]. We found that three spliced peptides were better 
produced by the standard proteasome than by the immunoproteasome, while another was more 
efficiently produced by the immunoproteasome [56]. This demonstrated that both proteasome types can 
perform the splicing reaction. However, we observed that the production of a given spliced peptide 
depended on the ability of the proteasome to perform the cleavages required to liberate the fragments 
that composed the spliced peptide. Additionally, this ability differed among the two proteasome subtypes. 
Of note, even though it was initially identified in tumor cells, peptide splicing is not restricted to tumor cells, 
but can also occur in non-tumor cells, such as melanocytes [59]. In vitro, it was produced using 
proteasomes originating from human erythrocytes, but also from yeast cells [22,75]. It is therefore 
expected that peptide splicing also occurs in the thymus, where spliced peptides should be expressed 
like any other self-peptides to establish natural immune tolerance, on the condition that the type of 
proteasome (standard or immunoproteasome) present in medullary thymic epithelial cells is adequate 
for the production of these peptides. 
The induction of T-cell immune responses is critically dependent on dendritic cells, which are 
professional antigen-presenting cells located mostly in lymph nodes. These cells uniquely express the 
set of cytokines and costimulatory molecules required to activate naive T-cells in an antigen-specific 
manner. This means that CTL responses will be induced only against antigenic peptides presented by 
dendritic cells. Dendritic cells contain immunoproteasomes and intermediate proteasomes (see below), 
but very little standard proteasome (Figure 1A) [32]. Therefore, they will mostly induce CTL responses 
against peptides produced by the immunoproteasome (or intermediate proteasomes), but not against 
peptides produced by the standard proteasome. Regarding anti-viral responses, this is not an issue, 
because viral infections usually trigger inflammation, which induces immunoproteasomes in infected cells, 
which therefore will present the adequate antigenic peptides. Indeed, immunoproteasome-dependent 
peptides were shown to be the dominant targets of anti-viral CTL responses [108]. However, in the case 
of anti-tumor immune responses, the situation is different, because tumor cells usually do not contain 
immunoproteasomes, unless they are exposed to inflammation, and therefore, they may not present  
the peptides against which the immune response was triggered by dendritic cells [106]. Moreover,  
as indicated above, a number of clinically relevant tumor antigens are produced by the standard proteasome, 
but not by the immunoproteasome, and therefore are not presented efficiently by dendritic cells [20,31]. 
Vaccination strategies aimed at inducing CTL against such antigens should therefore be adapted in order 
to by-pass processing by the proteasome of dendritic cells. This can be done by immunizing with short 
“pre-processed” synthetic peptides or with recombinant minigene constructs encoding only the short 
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peptide. This notion was first confirmed by a study comparing the CTL responses induced against the 
HLA-A2-restricted peptide, melan-A26-35, after vaccination of wild-type and 1i-knock-out HLA-A2 
transgenic mice with either the peptide-encoding minigene or the full-length melan-A [109]. Stronger 
responses were induced in wild-type mice when the immunization was performed using the minigene 
retroviral construct when compared to the full-length construct, and this difference was reduced in the 
1i-knockout mice, which developed stronger responses to the full-length construct than the wild-type 
mice. This confirmed that the immunoproteasome was responsible for the poor responses in wild-type 
mice. Another approach to induce CTL responses against standard proteasome-dependent peptides  
is to engineer dendritic cells so that they no longer contain immunoproteasomes, but only standard 
proteasomes. Dannull et al. successfully used this approach in humans, using siRNA for the catalytic 
immunosubunits. They showed that dendritic cells transfected with those siRNA and with RNA 
encoding full-length tumor antigens induced better anti-tumor CTL responses, not only in vitro, but also 
in vivo in melanoma patients [110,111]. 
As mentioned above, the immunodominance hierarchy of viral antigens is linked to their dependency 
on processing by the immunoproteasome. Indeed, studying CTL responses against various influenza, 
MCMV (mouse cytomegalovirus) and LCMV (lymphocytic choriomeningitis virus) peptides, several 
groups observed changes in the responses to these peptides in knockout mice for some of the 
immunoproteasome subunits [108,112–115]. Responses to antigenic peptides were generally decreased, 
but in some cases, responses were improved or remained stable. Interestingly, this ended up modifying 
the immunodominance hierarchy, with dominant epitopes becoming subdominant, and vice versa [108]. 
The modification of the responses observed in these different models were generally attributed to  
a difference in the processing of the antigenic peptide by the proteasome types and/or to an alteration of 
the T-cell repertoire in immunoproteasome-deficient animals [108,112,114]. This latter point implies 
that, in immunoproteasome-deficient animals, the negative selection operated in the thymus has led to 
the deletion of T-cell precursors recognizing those viral epitopes. Negative selection occurs in the thymic 
medulla, where medullary thymic epithelial cells (mTEC) present MHC class I-restricted peptides 
derived from a variety of self-proteins. This induces the selective deletion of T-cell precursors reactive 
to these peptides. The proteasome content of mTEC has not yet been clearly evaluated, but it is thought 
to mostly correspond to immunoproteasomes. Alteration of the anti-viral repertoire in immunoproteasome 
subunit-deficient animals therefore suggests that the absence of some immunoproteasome subunits in 
mTECs enables the expression of novel self-peptides that mimic the viral epitopes and lead to the 
deletion of the corresponding anti-viral T-cell precursors. 
Studying the role of the immunoproteasome in the establishment of a T-cell response to MCMV in 
wild-type and 5i/ mice, Hutchinson et al. observed that although acute responses to MCMV mostly 
targeted immunoproteasome-dependent peptides, memory responses targeted those two epitopes that 
showed the least dependency on the immunoproteasome [115]. Acute MCMV T-cell responses would 
therefore be elicited by cells containing some immunoproteasome. However, this response would not be 
totally efficient at destroying target cells infected by MCMV, as this virus impedes immunoproteasome 
formation through the action of M27, a protein that induces the proteasomal degradation of STAT2 and 
thereby inhibits the IFN response pathway [116]. Chronic responses to MCMV would then involve 
antigen-presenting cells containing only standard proteasomes and stimulating CTL against those epitopes 
that are the least dependent on the immunoproteasome. 
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4.1.2. Intermediate Proteasomes 
Using a unique set of antibodies directed against proteasome catalytic subunits, our group additionally 
described two alternative proteasome forms, which are intermediate between the standard and the 
immunoproteasome, and contain only one (5i) or two (1i, 5i) of the three catalytic subunits of the 
immunoproteasome (immunosubunits) (Figure 1A) [32]. The existence of intermediate proteasome 
forms had previously been inferred from the observation that a number of tissues contained only some 
of the three immunosubunits [117]. It is only the development of immunosubunit-specific antibodies 
able to capture proteasomes in their native form that allowed us to define the exact stoichiometry of the 
intermediate proteasomes that are found in human tissues [32]. The existence of only two forms of 
intermediate proteasomes, namely 5i and 1i–5i, is in agreement with the previous works dissecting 
the general rules for proteasome cooperative assembly [93,118], which is dependent on the nature of  
the subunit propeptides [119,120]. This cooperative assembly ensures a preferential incorporation of 
immunosubunits over standard subunits, where, e.g., incorporation of 2i is dependent on that of 1i [93]. 
This may explain why we did not detect the presence of intermediate proteasomes containing 2i.  
In addition, catalytic subunits are initially incorporated in an immature form, containing an N-terminal 
peptide that needs to be cleaved to liberate the N-terminal threonine of the mature active site [121].  
This maturation step occurs at the last stage of proteasome assembly, when two hemiproteasomes join 
together to form the final particle. Again, this ensures protection of the cellular proteins, as catalytic sites 
only become active when the final particle is assembled and confines the proteolytic activity to the inner 
chamber. Maturation of the immunosubunits is interdependent: 5i was shown to be required for the 
maturation of 1i and 2i [93]. This may explain why we did not detect intermediate proteasomes lacking 
5i. Because the proteasome particle contains two  rings, the existence of proteasomes containing  
an asymmetric assortment of immunosubunits and standard subunits is conceivable. Such asymmetric 
proteasomes were observed in cells transfected with a tagged 1 and exposed to IFN [122], but it 
remains unclear whether they exist in unmanipulated cells or tissues. The intermediate proteasomes  
we described were symmetric. We searched for asymmetric proteasomes containing 5 on one  ring 
and 5i on the other, and we did not find any in human liver and melanoma [32]. 
Interestingly, intermediate proteasomes 5i and 1i–5i represent 10% to 20% of the total proteasomes 
found in tumors and 30% to 50% of those found in liver, kidney, small bowel, colon and dendritic  
cells [32] (Figure 1A). Studying the specific cleavage properties of each proteasome type, we showed 
that intermediate proteasomes 5i and 1i–5i both display trypsin and chymotrypsin-like activities that 
are intermediate between those of the standard and the immunoproteasome. The caspase-like activity of 
intermediate proteasome 5i is similar to that of the standard proteasome, while this activity is low  
in intermediate proteasome 1i–5i. This is easily explained by the fact that the caspase-like activity  
is generally associated with the 1 subunit, which is present in the 5i intermediate proteasome and  
not in the 1i–5i intermediate proteasome [32]. Owing to their specific cleavage properties, 
intermediate proteasomes produce a unique set of antigenic peptides. The HLA-A2-restricted peptides, 
MAGE-A10254–262 and MAGE-C2191–200, are exclusively produced by the intermediate proteasome,  
1i–5i, while the HLA-A2-restricted peptide, MAGE-A3271–279, is processed only by intermediate 
proteasome 5i (Table 1) [32,38]. Hence, intermediate proteasomes enlarge the MHC class I repertoire 
to peptides that can be processed by both dendritic cells (containing immunoproteasomes and intermediate 
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proteasomes) and tumor cells (containing standard proteasomes and intermediate proteasomes) and 
might therefore represent valuable targets for cancer immunotherapy. Of note, the presence of intermediate 
proteasomes should also be taken into account when analyzing the role of the immunoproteasome  
in single-immunosubunit KO mice. 
4.1.3. Thymoproteasome 
A few years ago, Murata et al. discovered the existence of an additional proteasome catalytic subunit, 
called 5t, which is specifically expressed in the cortical thymic epithelial cells (cTEC) and is 
homologous to the 5 and 5i subunits [123,124]. The cTEC are responsible for positive selection,  
a process by which immature T-cell precursors able to bind to self-MHC class I/peptide complexes on 
cTEC are triggered to survive. The 5t subunit has a dramatic effect on the establishment of the CTL 
repertoire, as 5t-deficient mice display an 80% reduction of splenic CTL and do not survive influenza 
virus infection [123,125]. The 5t subunit is incorporated in the 20S proteasome instead of 5i  
along with 1i and 2i (Figure 1A) [123]. Incorporation of 5t into HEK-293T proteasomes induced  
a dramatic decrease of the chymotrypsin-like activity when compared to the 5-containing proteasome, 
while the trypsin-like and caspase-like activities were not affected [123]. This is in line with the fact  
that the S1 pocket of 5t is lined by hydrophilic amino acids, while that of 5 or 5i contains hydrophobic 
residues [123]. Using a unique set of antibodies recognizing peptide-bound or empty MHC class I molecules, 
Nitta et al. showed that cTECs from both wild-type or 5t/ mice express MHC class I molecules 
associated with peptides. Some of these peptides appeared unique to cTECs, as two specific peptide 
populations bound to H-2Kb were found to be differentially expressed in cTECs when compared to  
other APCs [125], suggesting that cTECs display a qualitatively distinct repertoire of MHC class I/peptide 
complexes. It was originally proposed that the low chymotrypsin-like activity of the thymoproteasome 
might produce low-affinity MHC class I ligands that may limit the duration or the avidity of  
the interaction of the peptide/MHC complexes with the TCR and facilitate positive selection [123,126]. 
However, recent work by Xing et al. showed that the half-life of MHC/peptide complexes on the surface 
cTEC and mTEC was similar, disagreeing with the idea that cTEC would carry unstable MHC 
complexes responsible for positive selection [127]. Moreover, similar surface MHC class I levels are 
found in 5t+/ and 5t/ cTECs [123]. To reconcile these observations, it was proposed that cTECs 
carried peptides binding MHC class I using alternative anchor positions or developed a mechanism 
enabling them to stabilize MHC class I molecules bearing low affinity peptides [128]. In the future,  
a more detailed analysis of the peptide repertoire found on cTECs might help to understand the role 
played by the thymoproteasome in the formation of an immunocompetent T-cell repertoire. 
4.1.4. Proteasome Subtypes and Negative Selection of T-Cell Precursors in the Thymus 
It is interesting to note that, so far, most tumor antigenic peptides found to be poorly processed by the 
immunoproteasome derive from self-proteins expressed in normal adult tissues (Table 1). Because the 
thymus contains abundant amounts of immunoproteasome, this precludes the processing of these 
peptides by the medullary thymic epithelial cells (mTEC), resulting in a lack of negative selection of  
T-cells recognizing these antigens and explaining why these T-cells persist in the periphery. In contrast, 
tumor antigens, which are better produced by the immunoproteasome, often correspond to MAGE-type 
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antigens encoded by cancer-germline genes or to mutated antigens [31,32,66]. The limited immune 
tolerance against MAGE-type antigens has been attributed to the very low expression of cancer-germline 
genes in mTEC, resulting in the negative selection of only those T-cells recognizing these antigens with 
a high avidity [129]. The anti-tumor T-lymphocytes present in the blood of cancer patients would then 
derive from low-avidity T-cells that escape negative selection in the thymus. To confirm this concept, 
our group recently produced knockout mice for a mouse cancer-germline gene, namely P1A [130].  
The expectation was that these mice, which are devoid of P1A expression in the thymus, should contain 
an unselected anti-P1A T-cell repertoire still containing high-affinity T-cells. Surprisingly, although the 
frequency of anti-P1A T-cells was slightly higher in P1A-KO mice, the anti-P1A T-cell repertoire of 
P1A-KO mice was barely different from that of wild-type mice, indicating that there is only minimal 
tolerance against this antigen in wild-type mice, despite detectable expression of P1A in mTEC [130]. 
Further analysis of the processing of the P1A antigen and of the type of proteasome contained in  
mTEC might help understanding the reason for the lack of tolerance against antigens encoded by  
cancer-germline genes. 
4.1.5. Structure-Related Properties 
The crystal structures of the mouse standard proteasome and the immunoproteasome were solved 
recently and revealed that the cleavage preferences of the immunoproteasome relied on subtle 
conformational changes in the substrate-binding pockets of catalytic subunits 1i and 5i [131].  
Indeed, the substrate-binding channel of 1i is lined with hydrophobic amino acids, resulting in an 
increased hydrophobicity and a decreased size of the binding pocket, thereby accounting for the higher 
cleavage activity of 1i after small hydrophobic and branched residues [131]. Compared to 5, 5i 
harbors a more spacious S1 pocket, favoring access to large non-polar residues and explaining the higher 
chymotrypsin-like activity of 5i [131]. Additionally, the vicinity of the active site of 5i is more 
hydrophilic: this is predicted to favor proteolysis by attracting water molecules, but also by stabilizing 
the tetrahedral intermediate through additional hydrogen bonds with the oxyanion hole [131]. 
Studying the processing of the HLA-A2-restricted peptide, MAGE-A10254–262, we observed that this 
peptide could only be processed by the intermediate proteasome 1i–5i and that the inability of the 
other proteasomes to produce the peptide was related to the occurrence of a destructive cleavage within 
the peptide after aspartate257 (D257) (Table 1) [32]. The caspase-like activity, which is defined by  
cleavage after acidic residues, is generally associated with the presence of the 1 subunit, and digestion 
of fluorogenic peptides showed that the intermediate proteasome 1i–5i and the immunoproteasome 
display a much lower caspase-like activity than the standard proteasome. However, in the case of  
the MAGE-A10254–262 peptide, the immunoproteasome still performed the destructive cleavage after D257, 
despite the presence of the 1i subunit. Therefore, the ability of the intermediate proteasome 1i–5i,  
as opposed to the immunoproteasome, to produce the antigenic peptide suggests that 2i negatively 
influences the production of this peptide, either because 2i itself displays sufficient caspase-like activity 
to destroy the peptide or because it affects the structure of the immunoproteasome and increases its 
ability to cleave after D257. Such an allosteric effect of one subunit on the activity of the others was 
previously suggested by Sijts et al. who showed that subunit 5i, by impacting the structure of the 20S 
proteasome, increases the activity of subunits 2i and 1i [132]. 
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4.1.6. Other Functions of the Immunoproteasome 
It is quite likely that the function of the different proteasome types is not restricted to antigen 
processing. The work of Seifert et al., for example, suggested a role for the immunoproteasome in the 
degradation of polyubiquitinated, oxidant-damaged proteins accumulating after IFN treatment [133]. 
However, the prominent role of the immunoproteasome in the degradation of polyubiquitinated proteins 
was not confirmed by others [134]. Another role for the immunoproteasome was suggested by the 
observation that the absence of 1i in NOD mice impaired the processing of the NF-B p105–p50 [135]. 
However, this study was refuted early after publication, and the function of the immunoproteasome  
in the NF-B signaling pathway has remained largely debated since then [136–140]. Interestingly,  
the use of the 5i-specific inhibitor, PR-957, affected the production of inflammatory cytokines IL-23, 
TNF- and IL-6 by endotoxin-stimulated peripheral blood mononuclear cells in an NF-B-independent 
manner [141]. The inhibitor also affected the production of IFN and IL-2 in stimulated T-cells and 
helped with controlling the pathogenic response in a mouse model of rheumatoid arthritis [141]. 
4.2. Proteasome Regulators 
As mentioned above, a key step in the control of proteasome activity is exerted at the level of substrate 
entry into the catalytic chamber of the particle and depends on the presence of regulators. 
4.2.1. The 19S Regulator 
The 19S regulator (PA700) is a large particle of about 700 kDa that associates with one or both sides 
of the 20S proteasome core to enable the proteasome to bind, deubiquitylate, unfold and translocate  
the protein substrate into the catalytic chamber. The 19S regulator specifically recognizes proteins 
targeted for degradation by the covalent attachment of ubiquitin molecules (74 amino acids in length)  
to lysine residues within protein substrates. The ubiquitination requires the sequential action of an 
ubiquitin-activating enzyme, E1, an ubiquitin-conjugating enzyme, E2, and an ubiquitin-ligase enzyme, 
E3 (reviewed in [142]). Additional ubiquitin molecules can then be ligated to a previously bound 
ubiquitin to form polyubiquitin chains. Chains of four or more ubiquitins are sufficient to target  
proteins for degradation. 
The 19S regulator is composed of at least 19 subunits that are assembled in two different parts: the 
lid and the base (reviewed in [2]). In yeast, the base comprises six ATPases (Rpt1-6), the two large  
non-ATPase subunits, Rpn1 and Rpn2, and two ubiquitin receptor subunits, Rpn10 and Rpn13.  
The six AAA-ATPase subunits, Rpt1-6, form a heterohexameric ring that directly contacts the  ring of 
the core 20S particle and is responsible for the ATP-dependent unfolding and translocation of  
the substrate into the chamber. The Rpn10 and Rpn13 subunits directly bind the polyubiquitin chains  
of protein substrates. The lid comprises nine Rpn subunits (Rpn3, 5–9, 11, 12 and 15). Subunits Rpn3, 
5, 6, 7, 9, 12 have very similar domain structures and comprise an N-terminal helix repeat segment,  
a proteasome-COP9/signalosome-eIF3 (PCI) domain and a long C-terminal helix [143]. The Rpn8 and 11 
subunits contain an Mpr1-Pad1-N-terminal (MPN) domain, and Rpn11 bears a deubiquitylation activity 
(DUB) [144,145]. The role of the other PCI and MPN subunits has not yet been characterized,  
except for Rpn6, whose crystal structure suggested a critical role in stabilizing the interaction between 
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the 20S core particle and the regulatory complex [146]. The 19S regulator can associate with one or  
both ends of the 20S proteasome particle, but can also be part of a hybrid proteasome composed of  
one 19S regulator and one PA28 or PA200 regulator bound to either end of the 20S proteasome  
complex (Figure 1B) [147,148]. 
4.2.2. The PA28 Regulator 
The PA28 regulator (11S regulator) was originally isolated owing to its ability to stimulate the 
hydrolysis by the 20S proteasome of small peptide substrates, but not intact, folded proteins [149–151]. 
It is composed of two subunits,  and , whose transcription is induced following exposure to  
IFN [152,153]. Electron-microscopic studies showed that the PA28 subunits assemble to form a  
ring-shaped heptameric complex with a 34 conformation that interacts with the -ring of the 20S 
proteasome complex [154–156]. The PA28 complex binds either to both ends of the 20S proteasome 
or to only one side of the particle, which binds a 19S regulator on the other side to form the so-called 
hybrid proteasome (Figure 1B) [147,157,158]. A number of mechanisms have been proposed to explain 
how PA28 increases proteasome activity, including the allosteric activation of the active sites of  
the proteasome [149] and the stimulation of peptide entry [159] or exit [160,161] from the 20S chamber. 
Other explanations include the coupling of the proteasome to chaperones that facilitate substrate delivery 
inside the catalytic chamber or the interaction of PA28-containing proteasomes with ER membranes to 
facilitate the transfer of the produced peptides into the ER lumen [151,162]. Studying antigen 
presentation in mice deficient for PA28, Preckel et al. showed that these mice, which lack both PA28 
and PA28, were impaired in their ability to process antigens [163]. In addition, these PA28-deficient 
cells displayed a dramatic decrease in immunoproteasome content, which, together with the fact that 
PA28 was found to be associated with immunosubunit-containing hemiproteasomes, led the authors to 
conclude that PA28 was necessary for immunoproteasome assembly [163]. Yet, in subsequent studies 
using PA28 and PA28 double-knockout mice, Murata et al. observed normal immunoproteasome 
assembly and normal immunity to influenza infection [164]. In this study, however, the authors observed 
that PA28/ cells were unable to process a peptide derived from the murine melanoma differentiation 
antigen, TRP2 (TRP2181–188). Overall, the authors concluded that PA28 was not required for proteasome 
assembly nor overall MHC class I presentation, but was, rather, involved in the processing of a subset 
of antigenic peptides [164]. Later on, several in vitro and in vivo studies highlighted a role for PA28 
in the processing of other MHC class I peptides (Table 2). In vitro digestions of precursor peptides by 
20S proteasomes in the presence or absence of recombinant PA28 showed that PA28 increases 
cleavage efficiency and the production of MHC ligands by the proteasome [165,166]. Association of the 
proteasome with PA28 also favors double cleavages, which was assumed to originate from the retention 
by PA28 of the peptide substrate inside the proteasome chamber, thereby increasing the probability for 
a second cleavage to occur [165]. Transfecting PA28 into mouse fibroblasts expressing the murine 
cytomegalovirus antigen pp89, Groettrup et al. observed a marked increase in recognition by the  
virus-specific cytotoxic T-cells [167]. In this system, presentation of the influenza nucleoprotein was 
also significantly improved. Later on, the same authors showed that the increase in antigen presentation 
of the pp89 peptide was independent of the proteasome-subunit composition and therefore, rather, 
resulted from the general ability of PA28 to activate proteasome complexes without affecting 
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proteasome-subunit composition [168]. Overexpression of PA28 also increased the presentation of  
a number of viral epitopes, while it did not affect the production of others [169,170]. Studying the role of 
PA28 on the processing of the peptide TRP2360–368 derived from the human melanoma differentiation 
antigen, TRP2 [171], Sun et al. observed that this peptide was not processed in a melanoma cell line 
lacking PA28, but this processing was rescued after transient transfection of PA28 cDNAs. Interestingly, 
the replacement of the flanking sequences of a PA28-independent antigenic peptide by those of  
the PA28-dependent peptide TRP2360–368, revealed that the terminal flanking sequence of the peptide 
TRP2360–368 was sufficient to confer PA28 dependency [172]. The origin of this sequence-driven 
dependency has not yet been clarified. Lastly, an allele-specific involvement of PA28 was observed, 
as it reduced the processing of Kd and Dd ligands, while favoring the presentation of Kb and  
Ld peptides [173]. Overall, PA28 appears not to be essential for the MHC class I processing pathway, 
but rather to be involved in the presentation of a selective set of antigenic peptides. 
Table 2. The effect on the proteasome regulator PA28 on the processing of viral and tumor 









Viral antigens     
Murine cytomegalovirus 
pp89168–176 
H-2Ld YPHFMPTNL + [167,168] 
Murine Moloney MuLV 
Gag-leader75–83 
H-2Db CCLCLTVFL + [169] 
Murine Moloney MuLV 
gp75-env189–196 
H-2Kb SSWDFITV  [169] 
LCMV nuceoprotein118–126 H-2Ld RPQASGVYM  [174] 
JAK1 tyrosine kinase355–363 H-2Kd  SYFPEITHI + [165] 
Influenza A/PR/8 
nucleoprotein146–154 
H-2Kd TYQRTRALV + [167] 
Murine tumor Antigens     
TRP2181–188 H-2Kb VYDFFVWL + [164] 
Human Tumor Antigen     
TRP2360–368 HLA-A2 TLDSQVMSL + [171,172] 
TRP2288–296 HLA-A2 SLDDYNHLV  [172] 
4.2.3. The PA28 
PA28 was first identified as the Ki antigen, target of autoantibodies in the sera of patients with 
systemic lupus erythematosus [175]. In contrast to PA28, PA28 is not induced by IFN and has a 
predominant localization in the nucleus [151], where it binds and activates the 20S proteasome as  
an active homoheptamer [176]. PA28-deficient mice display reduced body size and defects in cell 
proliferation [177,178]. PA28-deficient embryonic fibroblasts show defects in mitotic progression  
and increased apoptosis, suggesting that the regulator is involved in cell cycle progression and  
apoptosis [177,178]. Accordingly, several binding partners of PA28 were identified, whose functions 
are related to apoptosis, such as caspase-7 and MEKK3 [179,180]. Moreover, PA28 was shown to be 
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involved in the ubiquitin- and ATP-independent degradation of a number of cell-cycle regulatory 
proteins, such as the cyclin-dependent inhibitor p21, or the steroid receptor coactivator 3 (SRC-3),  
which is an oncogene often amplified in breast cancer and involved in cell growth [181,182].  
Recent studies have also shown that PA28 is involved in DNA repair and chromosome stability and  
takes part in the organization of the nuclear speckle and the trafficking of SR proteins (proteins with 
long serine and arginine repeats, involved in RNA splicing) to the transcription sites [183–185]. 
Interestingly, PA28 was shown to inhibit the activity of p53, a central transcription factor involved in 
cell cycle arrest and apoptosis, by inducing p53 nuclear export and promoting its MDM2-dependent 
ubiquitination and proteasome degradation [186,187]. The role of PA28 in the stability of p53 was 
recently shown to originate from the PA28-dependent degradation of casein kinase 1 (CK1), which 
negatively regulates MDM-2 [188]. Additionally, a negative feedback loop between p53 and PA28 
helps with maintaining the balance of p53 and PA28 in cells [189]. 
Contrary to PA28, which improves all three catalytic activities of the proteasome; PA28 was 
shown to selectively activate the trypsin-like activity without affecting the chymotrypsin-like and the 
caspase-like activities [190]. However, the role of PA28 in antigen processing appears relatively 
insignificant, as PA28-deficient mice display normal levels of MHC class I molecules and are not 
affected in their responses to influenza virus [178]. However, a slower clearance of the intracellular 
fungal pathogen Histoplasma capsulatum was observed, in parallel with a slight decrease in the number 
of total CD8+ T-cells in infected animals [178]. The origin of this defect was not identified. 
4.2.4. The PA200 Regulator 
PA200 is a 200 kDa protein originally identified in rabbit reticulocyte lysate and bovine testis,  
where it was bound to 20S proteasomes [148,191]. Similarly to the proteasome regulator, PA28, 
PA200 stimulates the proteasome hydrolysis of small peptides, but not folded proteins, and it does so  
in an ATP-independent manner [148]. Contrary to PA28, which activates all three proteasome 
catalytic activities, or to PA28, which activates only the trypsin-like activity, PA200 was shown  
to increase the hydrolysis of peptides bearing an acidic residue in P1 (caspase-like activity) [148].  
PA200 is particularly abundant in testis, where it might play an important role in the maturation of 
spermatozoa and in the progression of spermatogenesis. Interestingly, after gamma irradiation, cellular 
levels of PA200/19S hybrid proteasomes are increased [192], and the complex relocalizes to intranuclear 
foci [148], where PA200 accumulates on chromatin. This leads to an increase in proteasome-related 
caspase-like activity at the chromatin site [192]. Interestingly, PA200 knockdown was found to impair 
cell survival after gamma-irradiation [148], a phenomenon that could be counteracted by the addition of 
exogenous glutamine. This suggested that PA200-deficient cells are unable to cope with the increased 
glutamine demand that arises following irradiation. The reason for this is not yet clear, but it was 
suggested that the caspase-like activity of the PA200-19S hybrid proteasome might help with restoring 
the intracellular levels of glutamine or glutamate necessary for the long-term survival of tumor cells 
following radiation exposure [192]. So far, no involvement of PA200 in the production of antigenic 
peptides has been reported. 
  




The proteasome is a major regulator of protein homeostasis in cells. Through its function in protein 
degradation, the proteasome enables the cell to adapt to the various assaults and changes occurring in its 
environment. For each situation, a specific proteasome regulator is involved, granting access to protein 
substrates into the chamber. Proteasome activity is also regulated by its composition in catalytic subunits, 
which modulates the cleavage specificities of the particle. As a result of its protease activity,  
the proteasome releases small peptides that can be loaded onto MHC class I molecules and transported 
to the cell surface for recognition by the immune system. Proteasome regulation is an important 
parameter determining the type of peptides presented at the cell surface and thereby affecting the ability 
of the immune system to respond to the presence of viruses and tumor cells. This occurs at various levels 
including the establishment of an immunocompetent T-cell repertoire devoid of autoimmune reactivity, 
the activation of naive T-cells into active effectors cells and the recognition and destruction of tumor  
or virus-infected cells. Altogether, understanding the mechanisms involved in the production of 
antigenic peptides by the proteasome is of crucial importance in order to adapt the mode of delivery of 
immunotherapeutic vaccines and to define which peptides are the most likely to improve the clinical 
responses to viruses and cancer. 
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